To investigate the pathophysiology of ischemic heart disease (IHD), tourniquet ischemia on the upper limb was done and changes in platelet aggregation, plasma 6-keto-PGF
1α concentrations and plasma thromboxane B
2 (TXB
2) concentrations were studied. At rest, platelet aggregability and plasma TXB
2 concentrations were significantly increased in IHD patients compared with those in normal subjects (p<0.001 and p<0.001, respectively). In normal subjects, platelet aggregability, plasma 6-keto-PGF
1α concentrations and plasma TXB
2 concentrations rose significantly during ischemia (p<0.05, p<0.02 and p<0.05, respectively). In addition, plasma 6-keto-PGF
1α concentrations were significantly lower in IHD patients than in normal subjects during ischemia (p<0.005), though there was no significant change in the level of either group at rest. These results suggest that increase in prostacyclin synthesis in normal subjects during tourniquet ischemia may be a defense mechanism to maintain the balance between prostacyclin and thromboxane A
2 (TXA
2) and to prevent platelet aggregation induced by the procedure. Increase in platelet aggregation and TXA
2 generation in IHD patients at rest indicates a close correlation between IHD and platelet reactivity. Tourniquet ischemia induced a significant increase in prostacyclin generation in normal subjects but not in IHD patients, which suggests that production of prostacyclin was impaired in IHD patients during ischemia. A marked difference was obvious in prostacyclin and TXA
2 generation between IHD patients and normal subjects, and this difference may play an important role in the pathogenesis of IHD.
View full abstract